FINWIRES · TerminalLIVE
FINWIRES

TSX Closer: Index Down Again Friday As Global Economy May Soon Face Renewed Tariffs Spats

By

-- The Toronto Stock Exchange closed lower Friday following a day-prior surge that recovered all of the losses made over the prior five sessions, as U.S. President Donald Trump said he will lift the tariffs charged on cars and trucks from the European Union next week to 25%, potentially adding more pressures on a global economy already struggling with the fallout from the Middle East war.

The S&P/TSX Composite Index closed down 73.15 points, or 0.2%, to 33,891.18, with sectors mixed. Energy was down by more than 1%, while the Battery Metals Index rose 2.3% and Info Tech was up near 2%

Still FactSet noted that going in to today the index was up 1,196.29 points or 3.65% in April, and up 2,251.57 points or 7.1% year-to-date.

In its Monthly Equity Monitor for May 2026 published today National Bank noted equities are "riding exceptionally strong earnings expectations", with global markets reaching new highs despite an ongoing oil shock and persistent geopolitical risk. "Markets appear to be pricing in a rapid return to normal, but the Strait of Hormuz disruption continues to support a meaningful commodity-price premium," the bank said.

National Bank remains cautious on risk assets, as renewed escalation could have severe global consequences, while even de-escalation may leave inflation and rates higher for longer. AI productivity gains offer upside over time, but they may not arrive quickly enough to fully offset the near-term drag from the commodity-price shock, weaker real income, and higher interest rates, the bank added.

Meanwhile, on the economics front, Trump's latest threat against the EU comes as The Canadian Press reported Canada's Prime Minister Mark Carney is rejecting the notion that his government might use energy or critical minerals as "leverage" in upcoming trade talks with the U.S. administration. Carney is cited in an interview as saying he wouldn't describe those sectors as "leverage" since Canada is not talking about stopping any sort of existing trade. His comments come after United States Trade Representative Jamieson Greer told an audience in Washington that Canada should not attempt to use its energy and mineral resources as leverage in discussions about renewing the continental free trade pact, the report notes.

Of commodities, gold edged higher by midafternoon Friday but remained rangebound, even as the dollar and treasury yields rose while traders turn to bonds and also while the Iran War pushes up oil prices and boosts inflation and threatens higher interest rates. Gold for June delivery was up US$12.80 to US$4,642.40 per ounce.

But West Texas Intermediate crude oil closed lower as Iran made a new peace proposal, that U.S. President Trump rejected. WTI crude oil for June delivery closed down US$3.13 to US$101.94 per barrel, while July Brent oil was down US$2.17 to US$108.23.

Related Articles

Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.

$MRNA
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.

$GEHC
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Lennox International Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target to $569 from $559, 21.4x our 2027 EPS estimate (down to $26.57 from $26.62; our 2026 estimate down to $24.14 from $24.51), near LII's three- and five-year historical forward averages of 21.9x and 20.6x, respectively. We think LII faces material near-term operational challenges from residential market softness, escalating tariff-driven cost inflation (~5% vs. prior ~2.5% guidance), and margin compression in its Home Comfort Solutions segment (390-bp decline to 13.3% in Q1). However, these concerns are substantially mitigated by the Building Climate Solutions segment's exceptional performance (38% revenue growth, 300-bp margin expansion to 19.7% in Q1), significantly improved operating cash flow ($16.1M vs. -$35.8M Y/Y) due to inventory normalization. We note an antitrust class action lawsuit, filed in March, alleging price-fixing among HVAC equipment manufacturers since January 2020, posing an additional risk to LII's financial and reputational standing.

$LII